David W. Andrews, MD

Anthony Alfred Chiurco, MD Professor, Neurological Surgery

David W. Andrews, MD


909 Walnut Street
COB, 2nd Floor
Philadelphia, PA 19107

Email David Andrews

215-503-7038 fax

David W. Andrews, MD

Anthony Alfred Chiurco, MD Professor, Neurological Surgery


Medical School

MD, University of Colorado


Cornell Medical Center - New York Hospital


Memorial Sloan-Kettering Cancer Center, NY


Board Certification

Neurological Surgery

Hospital Appointment

Thomas Jefferson University Hospital
Methodist Hospital Division of Thomas Jefferson University Hospital

Anthony Alfred Chiurco Professor of Neurological Surgery

Associate Training Program Director

Director, Division of Neuro-oncologic Neurosurgery and Stereotactic Radiosurgery

Director, Stereotactic Radiosurgery Units, Jefferson Hospital for Neuroscience

Expertise & Research Interests

Dr. Andrews is currently the Emeritus Chief of the Tumor Division and established the Tumor Division in 1995. As junior faculty he was awarded a K-11 Physician Scientist Award from the NIH to conduct research in glioblastoma. He established the multi-disciplinary Brain Tumor Board in 1995 and convened the first multi-disciplinary Brain Tumor Clinic in 2008 that has convened continuously since its inception. In 2017, he was awarded as the inaugural recipient the Anthony Alfred Chiurco, MD Endowed Professorship in Neurosurgery. Dr. Andrews performs neurosurgical procedures and stereotactic radiosurgery—operations using precisely focused, high-dose radiation beams—to treat patients with brain tumors and published the landmark paper for the treatment of brain metastases in Lancet in 2004.

He is also a path-breaking researcher and has developed a neo-antigen immunotherapy to attack cells in glioblastoma, an aggressive and incurable brain cancer. The promising treatment uses cancer cells from the patient’s tumor to custom-design a vaccine that blocks tumor growth and helps reactivate the immune system to fight the cancer. He has formed a company, Imvax, and currently serves as the Chief Medical Officer. Under the leadership of its CEO John Furey, Imvax has raised over $150M to accelerate translational research for glioblastoma and other solid tumors with high unmet need. Dr. Andrews has been named in Philadelphia Magazine as a Top Doc in Neurosurgery continuously since 2005.


6,541,036; 6,096,019; 5,810,760